Lactobacillus Plantarum -derived extracellular vesicles protect against ischemic brain injury via the microRNA-101a-3p/c-Fos/TGF-β axis cross-species

zhang yang,Zidan Gao,Yifan Zhang,Hongqun Chen,Xuexia Yang,Xuming Fang,Yingwu Zhu,Jiayan Zhang,Fu Ouyang,Jun Li,Gang Cai,Xiang Lin,Xiaofang Shi,Lan Chu

DOI: https://doi.org/10.21203/rs.3.rs-1269337/v1

2022-01-28

Abstract:Abstract Objective As nanoscale membrane vesicles, extracellular vesicles (EVs) are actively released by cells and have recently been observed to assume an important role in the treatment of ischemic stroke. However, the source of EVs currently reported for the treatment of ischemic stroke is tightly restricted to mammals. Moreover, these EVs are limited in clinical translation due to the high cost of cell culture. In species other than mammals, Lactobacillus Plantarum culture is low-cost and high-yield. Notwithstanding, it is poorly identified whether Lactobacillus Plantarum -derived EVs (LEVs) can be applied across species for the treatment of ischemic stroke. Methods LEVs were injected into mice via the tail vein immediately after transient middle cerebral artery occlusion (tMCAO) modeling. Infarct volumes, neurological scores, and neuron apoptosis were examined 3 days following the ischemic episode. The expression of microRNA (miRNA) and the target gene in neurons and peri-infarct regions of the post-ischemic brain were measured for mechanistic analyses. Results LEVs crossed the blood-brain barrier and were taken up by neurons both in vitro and in vivo. LEV treatment attenuated neuron apoptosis following oxygen-glucose deprivation (OGD). In vivo findings displayed that LEV treatment substantially reduced neurological deficits and brain infarct size in tMCAO mice. High-throughput sequencing exhibited that miR-101a-3p expression was prominently elevated by LEV treatment in OGD-induced neurons, and corroborating findings were detected in tMCAO mice treated with LEVs. Mechanistically, c-Fos was directly targeted by miR-101a-3p. Moreover, c-Fos manipulated ischemia-induced neuron apoptosis in vitro and in vivo through the TGF-β1 pathway. miR-101a-3p inhibition aggravated ischemia-induced neuron apoptosis in vitro and in vivo, and miR-101a-3p overexpression triggered opposite results. Conclusion Our results elaborated for the first time that LEVs might inhibit neuron apoptosis and injury across species via the miR-101a-3p/c-Fos/TGF-β axis, which may provide novel ideas and targets for the treatment of ischemic stroke and is also of significance for the clinical translation of EVs.